KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Treasury Shares: 2012-2024

Historic Treasury Shares for Emergent BioSolutions (EBS) over the last 13 years, with Dec 2024 value amounting to $227.7 million.

  • Emergent BioSolutions' Treasury Shares rose 6.94% to $243.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $243.5 million, marking a year-over-year increase of 6.94%. This contributed to the annual value of $227.7 million for FY2024, which is negligibly% changed negligibly from last year.
  • As of FY2024, Emergent BioSolutions' Treasury Shares stood at $227.7 million, which was down 0.00% from $227.7 million recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' Treasury Shares registered a high of $5.6 million during FY2022, and its lowest value of $1.2 million during FY2020.
  • In the last 3 years, Emergent BioSolutions' Treasury Shares had a median value of $5.6 million in 2024 and averaged $5.6 million.
  • Data for Emergent BioSolutions' Treasury Shares shows a peak YoY spiked of 284.34% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Treasury Shares stood at $39.6 million in 2020, then soared by 284.34% to $152.2 million in 2021, then surged by 49.61% to $227.7 million in 2022, then remained steady at $227.7 million in 2023, then remained steady at $227.7 million in 2024.